Tg Therapeutics (TGTX) EBIAT (2016 - 2025)
Tg Therapeutics (TGTX) has 10 years of EBIAT data on record, last reported at $23.0 million in Q4 2025.
- For Q4 2025, EBIAT fell 1.26% year-over-year to $23.0 million; the TTM value through Dec 2025 reached $447.2 million, up 1812.41%, while the annual FY2025 figure was $447.2 million, 1812.41% up from the prior year.
- EBIAT reached $23.0 million in Q4 2025 per TGTX's latest filing, down from $390.9 million in the prior quarter.
- Across five years, EBIAT topped out at $390.9 million in Q3 2025 and bottomed at -$93.3 million in Q4 2021.
- Average EBIAT over 5 years is -$4.4 million, with a median of -$25.1 million recorded in 2022.
- Peak YoY movement for EBIAT: crashed 96.59% in 2024, then soared 9974.61% in 2025.
- A 5-year view of EBIAT shows it stood at -$93.3 million in 2021, then grew by 15.93% to -$78.5 million in 2022, then surged by 81.63% to -$14.4 million in 2023, then soared by 261.84% to $23.3 million in 2024, then dropped by 1.26% to $23.0 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were $23.0 million in Q4 2025, $390.9 million in Q3 2025, and $28.2 million in Q2 2025.